Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Wexler

Showing results (221-230 of 287) with videos related to

Pageof 29
Sort By:
JAMA Network Open|October 27, 2021
Association of Sodium-Glucose Cotransporter-2 Inhibitors With Fracture Risk in Older Adults With Type 2 DiabetesMin Zhuo, Chelsea E Hawley, Julie M Paik, et al.
BMJ (Clinical Research Ed.)|October 22, 2024
Glucagon-like peptide-1 receptor agonists before upper gastrointestinal endoscopy and risk of pulmonary aspiration or discontinuation of procedure: cohort studyWajd Alkabbani, Karine Suissa, Kristine D Gu, et al.
Diabetes, Obesity & Metabolism|November 3, 2021
Effectiveness and safety of empagliflozin in routine care patients: Results from the EMPagliflozin compaRative effectIveness and SafEty (EMPRISE) studyElisabetta Patorno, Ajinkya Pawar, Deborah J Wexler, et al.
Annals of Internal Medicine|January 17, 2022
Sodium-Glucose Cotransporter-2 Inhibitors Versus Glucagon-like Peptide-1 Receptor Agonists and the Risk for Cardiovascular Outcomes in Routine Care Patients With Diabetes Across Categories of Cardiovascular DiseaseElisabetta Patorno, Phyo T Htoo, Robert J Glynn, et al.
Obesity (Silver Spring, Md.)|September 1, 2022
Results of a 2-year lifestyle intervention for type 2 diabetes: the Reach Ahead for Lifestyle and Health-Diabetes randomized controlled trialDeborah J Wexler, Yuchiao Chang, Douglas E Levy, et al.
Plos One|December 11, 2013
The association of maximum body weight on the development of type 2 diabetes and microvascular complications: MAXWEL studySoo Lim, Kyoung Min Kim, Min Joo Kim, et al.
Annals of Internal Medicine|September 27, 2021
Sodium-Glucose Cotransporter-2 Inhibitors Versus Glucagon-like Peptide-1 Receptor Agonists and the Risk for Cardiovascular Outcomes in Routine Care Patients With Diabetes Across Categories of Cardiovascular DiseaseElisabetta Patorno, Phyo T Htoo, Robert J Glynn, et al.
Contemporary Clinical Trials Communications|June 14, 2019
Effective recruitment for practice-based research: Lessons from the REAL HEALTH-Diabetes StudyValerie Goldman, Amy Dushkin, Deborah J Wexler, et al.
Plos One|January 11, 2014
Salivary inflammatory mediator profiling and correlation to clinical disease markers in asthmaFrédéric F Little, Diana M Delgado, Philip J Wexler, et al.
Diabetes Care|January 26, 2021
Comparative Effectiveness and Safety of Sodium-Glucose Cotransporter 2 Inhibitors Versus Glucagon-Like Peptide 1 Receptor Agonists in Older AdultsElisabetta Patorno, Ajinkya Pawar, Lily G Bessette, et al.
Pageof 29

Showing results (221-230 of 287) with videos related to

Sort By:
Pageof 29
JAMA Network Open|October 27, 2021
Association of Sodium-Glucose Cotransporter-2 Inhibitors With Fracture Risk in Older Adults With Type 2 DiabetesMin Zhuo, Chelsea E Hawley, Julie M Paik, et al.
BMJ (Clinical Research Ed.)|October 22, 2024
Glucagon-like peptide-1 receptor agonists before upper gastrointestinal endoscopy and risk of pulmonary aspiration or discontinuation of procedure: cohort studyWajd Alkabbani, Karine Suissa, Kristine D Gu, et al.
Diabetes, Obesity & Metabolism|November 3, 2021
Effectiveness and safety of empagliflozin in routine care patients: Results from the EMPagliflozin compaRative effectIveness and SafEty (EMPRISE) studyElisabetta Patorno, Ajinkya Pawar, Deborah J Wexler, et al.
Annals of Internal Medicine|January 17, 2022
Sodium-Glucose Cotransporter-2 Inhibitors Versus Glucagon-like Peptide-1 Receptor Agonists and the Risk for Cardiovascular Outcomes in Routine Care Patients With Diabetes Across Categories of Cardiovascular DiseaseElisabetta Patorno, Phyo T Htoo, Robert J Glynn, et al.
Obesity (Silver Spring, Md.)|September 1, 2022
Results of a 2-year lifestyle intervention for type 2 diabetes: the Reach Ahead for Lifestyle and Health-Diabetes randomized controlled trialDeborah J Wexler, Yuchiao Chang, Douglas E Levy, et al.
Plos One|December 11, 2013
The association of maximum body weight on the development of type 2 diabetes and microvascular complications: MAXWEL studySoo Lim, Kyoung Min Kim, Min Joo Kim, et al.
Annals of Internal Medicine|September 27, 2021
Sodium-Glucose Cotransporter-2 Inhibitors Versus Glucagon-like Peptide-1 Receptor Agonists and the Risk for Cardiovascular Outcomes in Routine Care Patients With Diabetes Across Categories of Cardiovascular DiseaseElisabetta Patorno, Phyo T Htoo, Robert J Glynn, et al.
Contemporary Clinical Trials Communications|June 14, 2019
Effective recruitment for practice-based research: Lessons from the REAL HEALTH-Diabetes StudyValerie Goldman, Amy Dushkin, Deborah J Wexler, et al.
Plos One|January 11, 2014
Salivary inflammatory mediator profiling and correlation to clinical disease markers in asthmaFrédéric F Little, Diana M Delgado, Philip J Wexler, et al.
Diabetes Care|January 26, 2021
Comparative Effectiveness and Safety of Sodium-Glucose Cotransporter 2 Inhibitors Versus Glucagon-Like Peptide 1 Receptor Agonists in Older AdultsElisabetta Patorno, Ajinkya Pawar, Lily G Bessette, et al.
Pageof 29